Atossa Therapeutics Gives Final Dose in Breast Cancer Prevention Study | NASDAQ:ATOS

Proactive InvestorsMay 15 05:40 ET

Atossa Therapeutics Announces Last Patient, Last Dose in Its Phase 2 Karisma-Endoxifen Clinical Trial

SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company") today announced that the last patient in the Company's Karisma-Endoxifen clinical trial

Atossa TherapeuticsMay 15 00:00 ET

Atossa Therapeutics' Endoxifen Shows Promising Phase 2 Results, Secures Buy Rating

TipRanksMay 14 13:35 ET

Express News | Cantor Fitzgerald Reiterates Overweight on Atossa Therapeutics

BenzingaMay 14 09:25 ET

Express News | Atossa Therapeutics Files for Mixed Shelf of up to $100 Mln - SEC Filing

ReutersMay 13 16:06 ET

Atossa Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Atossa Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMay 13 13:05 ET